Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932122 | 0.83 | KMT2A (0.44) | KMT2AMEN1MAPTLMNAPDE4A | |
| SCHEMBL27521810 | 0.83 | PDE4A (0.60) | KMT2AMAPTLMNAPDE4APOLB | |
| SCHEMBL9966844 | 0.80 | IKBKB (0.41) | POLB | |
| SCHEMBL27368676 | 0.80 | ALDH1A1 (0.58) | KMT2AMEN1MAPTPDE4APDE4B | |
| SCHEMBL30994913 | 0.79 | HIF1A (0.40) | KMT2AMEN1MAPTLMNACA12 | |
| SCHEMBL9966843 | 0.79 | HIF1A (0.40) | KMT2AMEN1MAPTLMNACA12 | |
| SCHEMBL21641531 | 0.79 | NMT1 (0.34) | KMT2AMEN1POLBCA12CA1 | |
| SCHEMBL27792295 | 0.77 | NPY1R (0.48) | KMT2AMEN1MAPTLMNAPOLB | |
| SCHEMBL4872476 | 0.77 | PDE4B (0.45) | LMNAPDE4APDE4BPDE4DPDE4C | |
| SCHEMBL28014794 | 0.77 | GPR6 (0.48) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| EP-0745063-B1 | SUBSTITUTED BIPHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | AMERICAN HOME PROD (US) | 1999-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | KMT2A 2384/4885MEN1 2310/4885MAPT 4604/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | KMT2A 2384/4885MEN1 2310/4885MAPT 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.